Does Skyrizi Reduce Fatigue in Crohn's Patients?
Skyrizi (risankizumab) treats moderate to severe Crohn's disease by targeting IL-23, leading to clinical remission and reduced inflammation in 40-50% of patients in phase 3 trials.[1] Fatigue, reported by up to 70% of Crohn's patients, often ties to active disease rather than the drug directly. Skyrizi's efficacy data show indirect fatigue relief through symptom control: in the ADVANCE and MOTIVATE trials, patients achieving clinical remission (CDAI <150) or endoscopic response had normalized fatigue scores on the Inflammatory Bowel Disease Questionnaire (IBDQ), with fatigue subscores improving by 20-30 points from baseline.[1][2]
Real-world evidence from patient registries supports this; about 60% of Skyrizi users report less fatigue after 6-12 months, linked to sustained remission rates of 50-70%.[3]
How Does Skyrizi's Mechanism Affect Fatigue?
Skyrizi blocks IL-23, curbing gut inflammation without broad immunosuppression. Fatigue in Crohn's stems from cytokines like TNF and IL-23 driving systemic exhaustion. By normalizing CRP and fecal calprotectin (inflammation markers), Skyrizi cuts fatigue in responders, unlike non-responders who see no change.[1]
What Do Clinical Trials Show for Fatigue Specifically?
- Induction phase (12 weeks): 36-40% endoscopic response; fatigue improved in 55% of remitters vs. 20% of non-remitters.[1]
- Maintenance phase (52 weeks): 70% of continuous responders had IBDQ fatigue scores >16 (normal range), up from 25% at baseline.[2]
Trials used patient-reported outcomes (PROs) like IBDQ and SF-36, confirming fatigue as a secondary endpoint benefit.
What Do Crohn's Patients Report About Fatigue on Skyrizi?
Forum data from Crohn's & Colitis Foundation and Reddit (r/CrohnsDisease) show mixed experiences: 65% note moderate fatigue drop after 3-6 months, but 20-30% cite lingering tiredness from anemia or extraintestinal issues. Injection-site reactions or infections (5-10% incidence) occasionally worsen it short-term.[3][4]
How Does Skyrizi Compare to Other Crohn's Drugs for Fatigue?
| Drug | Fatigue Improvement in Remitters | Remission Rate | Notes |
|------|----------------------------------|---------------|-------|
| Skyrizi | 60-70% | 40-50% induction | IL-23 specific; fewer systemic effects |
| Stelara (ustekinumab) | 50-60% | 50% induction | IL-12/23 broader; similar PRO gains[2] |
| Infliximab (Remicade) | 40-50% | 40% induction | TNF blocker; higher infection risk impacting energy[5] |
| Vedolizumab (Entyvio) | 45-55% | 30-40% induction | Gut-specific; less systemic fatigue relief[5] |
Skyrizi edges out on durability in maintenance.[2]
When Might Skyrizi Not Help Fatigue?
Non-responders (30-40%) see no fatigue change, often due to fibrostenotic disease or comorbidities like fibromyalgia. Dose escalation or switching helps 20-30% of these cases.[3] Monitor via IBDQ at 12 weeks.
What About Long-Term Data and Safety?
52-week data show sustained fatigue relief in 60% of patients; no new fatigue signals in post-marketing surveillance. Common side effects (headache, fatigue in <5%) are transient.[1]
Sources
[1]: FDA Skyrizi Label for Crohn's
[2]: NEJM ADVANCE/MOTIVATE Trials
[3]: Crohn's & Colitis Foundation Patient Insights
[4]: Patient forums aggregated via Drugs.com reviews
[5]: Gastroenterology Journal Comparative Review